ARTICLE SUMMARY:
The US launch of the Liberant ultrasonic controlled thrombectomy system was the first milestone in Medtronic’s move into the fast-growing peripheral market. Emerging innovators accelerate the treatment of tricuspid valve disease, which has lagged other CV interventions. Median Technologies gains FDA clearance for its eyonis LCS AI-based lung cancer screening device and from Market Pathways, Boston Scientific's quest for reimbursement of its Intracept chronic low back pain technology.
